This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish (read more).


Highly Potent Active Pharmaceutical Ingredients

The HPAPI global market has developed rapidly in the past year and is continuing to expand into the future

With over a quarter of drugs in development worldwide being classified as highly potent. As a result, there is a growing demand for both pharmaceutical and contracted manufacturers to adapt to the evolving HPAPI landscape.

The event will explore current market trends, challenges of correctly assessing hazard, the use of innovative containment solutions to minimize risk and advanced manufacturing processes. In addition, the conference aims to guide attendees through novel regulatory updates for each stage of HPAPI development.

PCI’s Dave O’Connell will be speaking at HPAPI. Come by and speak to us about your HPAPI needs

Visit the event website here:

Date & Time

13 May 2019 - 14 May 2019 - All Day


Copthorne Tara Hotel
Scarsdale Place, Kensington
Greater London
W8 5SY
United Kingdom

Loading Map....

PCI Welcomes New Chief Financial Officer and SVP, Serge Dupuis

PCI is pleased to welcome Serge Dupuis as Senior Vice President and Chief Financial Officer. Serge’s appointment supports PCI’s continued... View Article

Jeremy Osborne to Share his Expertise on Accelerating into Early Clinical Trials

PCI will share our specialist clinical trials expertise at the upcoming Clinical Trial Supply New England Conference. PCI’s Jeremy Osborne,... View Article